Prima System Restores Vision for Macular Degeneration Patients
A novel retinal implant bypasses damaged photoreceptors to restore sight in AMD patients.
1Addressing Vision Loss
Age-related macular degeneration impacts over 5 million individuals globally, creating central vision blind spots. Previously, no effective treatment existed to restore sight for these patients. The Prima system offers a breakthrough by utilizing a retinal implant and camera-equipped glasses to bypass damaged cells, enabling users to perform daily tasks like reading.
2Biological Mechanism
The retina processes light through three distinct cell layers: photoreceptors, bipolar cells, and ganglion cells. In AMD, only the light-converting photoreceptors die off, while the rest of the circuitry remains functional. The Prima implant replaces these lost photoreceptors, effectively mimicking their natural role to transmit visual information directly to the brain.
3Real-Time Image Capture
The system utilizes glasses equipped with a miniature front-facing camera to capture visual data in real time. This feed operates at roughly five megapixels with a frame rate of 30 frames per second, comparable to standard television quality. Raw video data is then transmitted to a handheld processor via a fiber-optic cable.
4Signal Processing Hardware
A portable, handheld processor converts the raw video feed into infrared light signals. This device provides users with physical controls to manually adjust contrast, brightness, and zoom levels. By routing these signals back to the glasses, the system prepares the visual data for projection directly into the patient's eye for processing.
5Infrared Projection Technology
A laser projector mounted on the glasses shines pulses of near-infrared light at 880 nanometers toward the eye. This specific wavelength is invisible to the human eye, allowing the signal to pass through the pupil. The light reaches the retinal implant located at the back of the eye to trigger visual responses.
6Implant Design Specifications
The implant consists of 378 individual pixels, each containing an electrode and two photovoltaic cells. These cells perform dual functions: they convert incoming light into electrical currents that stimulate healthy bipolar and ganglion cells, and they act as solar cells to power the chip, removing the need for an internal battery.
7Clinical Efficacy Results
Following specialized training sessions, over 80% of patients using the Prima system demonstrated significant functional improvements. Users reported the ability to read text, complete crossword puzzles, and operate mobile phones effectively. These results highlight the system's potential to restore independence for those suffering from advanced stages of macular degeneration.
8Regulatory and Future Outlook
The Prima system received approval in Europe during July and is currently awaiting FDA clearance in the United States. Developed by the California-based Science Corporation, the technology leverages the body's natural functions to process visual information. This innovation marks a significant shift in how medical professionals approach degenerative retinal conditions.